BioNTech eases 2024 revenue outlook despite hefty Covid vaccine third-quarter...
Despite strong third-quarter revenues, BioNTech has softened its 2024 sales guidance in light of changes to Covid-19 vaccine uptake, pricing and seasonal variations. The company’s €1.2 billion ($1.3...
View ArticleRare disease biopharma companies weigh in on FDA's new innovation hub
AstraZeneca's Alexion, BridgeBio, BioMarin, Ultragenyx and others, including Sen. Bob Casey (D-PA), recently weighed in on the details of a new cross-cutting FDA collaboration hub focused on rare...
View ArticleThe election is Tuesday. What’s at stake for the pharma industry?
The biopharma industry has been a bipartisan political target in recent years. But in the 2024 presidential election, details are scarce around key issues that could impact drugmakers. Drug pricing has...
View ArticleFDA cites Mark Cuban's drug compounding center in Dallas with sterility,...
The FDA is raising sterility and other quality concerns with Mark Cuban's Cost Plus Drugs compounding facility in Dallas, following a nine-day inspection of the site in August and September. A
View Article